Marriott International news
The WiseView Research desk's stories that name Marriott International, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The MAR page →
- HeadlineMarriott (MAR) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- HeadlineAre Consumer Discretionary Stocks Lagging Marriott International (MAR) This Year?
- HeadlineMarriott International (MAR) Reports Next Week: Wall Street Expects Earnings Growth
- HeadlineMarriott International (MAR) Just Flashed Golden Cross Signal: Do You Buy?
- HeadlineWill Marriott (MAR) Beat Estimates Again in Its Next Earnings Report?
- HeadlineThese 2 Consumer Discretionary Stocks Could Beat Earnings: Why They Should Be on Your Radar
- CongressRo Khanna sold $1,001 - $15,000 of MAR
- HeadlineMarriott International Announces Release Date For Third Quarter 2026 Earnings
- HeadlineThe Rise of Place: Marriott International Reveals Asia Pacific's Future of Food
- HeadlineTHE RITZ-CARLTON NAPLES, TIBURÓN REVEALS TRANSFORMED RESORT AND DYNAMIC CULINARY CONCEPTS
- HeadlineLisata subsidiary Marea treats first patient in MAR002 acromegaly trial
- HeadlineMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
- CongressVal Hoyle sold $1,001 - $15,000 of MAR
- CongressSusie Lee sold $1,001 - $15,000 of MAR
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.